New product launches helped GlaxoSmithKline Pharmaceuticals (GSK), the Indian arm of the world’s second largest drug maker, post a 6.9 per cent increase in net profit to Rs 141 crore for the quarter ended September, against Rs 132 crore in the same quarter last year.
Net sales of GSK India were up 12 per cent during the quarter, at Rs 511.8 crore against Rs 457 crore in the same period last year.
“Recent launches of Tykerb for breast cancer, anti-hypertensive drug Benitec from Daiichi Sankyo and Cervarix for cervical cancer are making steady progress. Vaccines have recorded strong growth too,” MD Hasit B Joshipura said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app